Quick ReadPlain-language overview · read this first
Unimicron Technology is a leading Taiwanese manufacturer of high-end printed circuit boards. It supplies customers in chip packaging and servers, and is one of the named suppliers in the AI and server boom. The report's stance is clear: the company itself is solid, but the current price is far too expensive, so it recommends Avoid.
Its profits mainly come from process capability and scale. It makes technically demanding substrates and high-density boards, rather than earning a premium through brand power. Demand for this business exists over the long term, but the issue is that it rises and falls sharply with the industry cycle. It is not the kind of business that becomes steadily more stable as it grows. One figure captures the problem best: after costs, how much is left from every 100 in sales. In the strong cycle of 2022, nearly 36 was left; by 2025, less than 14 was left. Profitability has thinned substantially, showing that the strength in 2022 was more a matter of catching a good year.
More importantly, the earnings on the books have not turned into cash that can be distributed to shareholders. In both 2024 and 2025, the company did make money, but because it spent heavily on expanding plants, cash was a net outflow after everything was counted. In other words, the profits are real, but a large share of them does not stay with the company.
What about the current price? This is the report's biggest concern. Based on its current profits, buying the whole company would take more than a hundred years to earn back the purchase price, meaning many years of future good news have already been paid for upfront. The report estimates a reasonable purchase price at roughly 90 to 150 per share, while the current share price has already reached 911, far above that range. The biggest risk is not that the company goes bankrupt, but that once the excitement fades, the valuation returns to normal and the price falls sharply.
The above is only an explanation of this report and is not investment advice. The stock market involves risk; invest with caution.
LeadUnimicron is a leading Taiwanese PCB and IC substrate manufacturer whose revenue mix has shifted toward high-end ABF substrates and HDI. The core thesis is that AI server demand may lift the cycle, but heavy capex, volatile margins, and weak free cash flow make the current price hard to justify. Research rating Avoid: a capable cyclical manufacturer, but the valuation leaves no acceptable margin of safety.
Prices in the article are as of publication; see the valuation band above for the live price.
Note: The analysis below relies mainly on the company's official investor briefings, TWSE company profile, TWSE monthly revenue tables, and Reuters/LSEG. Because some TWSE annual report PDFs could not be stably accessed in the current retrieval environment, I cross-checked the annual financial summaries in the company's official investor presentations against the TWSE company page and Reuters financial pages. Where an item cannot be confirmed, I state "unknown" or "additional information required." As of 2026-06-09, Reuters showed Unimicron's latest delayed quote at about NT$911/share, with market capitalization of roughly NT$1.447 trillion; the TWSE company profile showed share capital of about NT$15.889 billion.
Conclusion First
Investment Rating: Avoid
Core view: Unimicron is an understandable manufacturing business with real process and scale capabilities in high-end substrates and HDI, but it is not the Buffett-style great business that naturally earns high returns, consumes little capital, and has strong pricing power. Profitability and gross margin fluctuated sharply from 2020 to 2025. Although growth recovered in 2024 and 2025, free cash flow remained negative, which means accounting profit did not smoothly convert into distributable cash flow. More importantly, the valuation implied by the current share price is far above the range I can accept based on Owner Earnings, asset value, and relative valuation. This is a combination of a good-business fragment, a powerful industry narrative, and a very poor purchase price.
Is there a margin of safety at the current price: No
Suitable investor type: More suitable for industry/cyclical investors who can tolerate both business-cycle and valuation volatility and are willing to track the ABF/substrate cycle; less suitable for conservative long-term value investors whose core discipline is margin of safety.
Biggest uncertainties:
The extent to which AI/HPC-related demand can structurally lift Unimicron's profit profile, rather than merely creating a temporary boom.
In Q1 2026, non-operating income accounted for a large share of earnings, and its sustainability is highly questionable.
The current market valuation has already prepaid a large amount of future good news. The largest future risk looks more like valuation mean reversion than a small earnings fluctuation.
Direct answers to the seven core questions:
Is this a business I can understand? Yes.
Is it a good business? Above average, but highly cyclical and not elegant enough.
Does it have durable competitive advantages? It has some advantages, but not a very wide moat.
Is management trustworthy, and is capital allocation rational? Basically qualified, but capital allocation is conservative and steady with dilution; it is not excellent.
Can it generate real, distributable cash flow over the long term? It can generate real operating cash flow, but distributable cash flow is highly volatile and has been consumed by high capex in the past two years.
Is there enough margin of safety at the current price? No.
What facts would overturn the investment judgment? If Owner Earnings can stabilize at the NT$25 billion to NT$30 billion level over the next 2 to 3 years, capex intensity clearly declines, and gross margin can stay around or above 20%, then my view that the current valuation is too high would need to be reassessed.
Business Understanding
What is the core business? Unimicron is essentially an electronics manufacturing company centered on PCB, HDI, IC substrates, and FPC. The TWSE company profile defines it as a supplier focused on PCB and substrate manufacturing; Reuters also describes its main businesses as PCB, HDI, FPC, rigid-flex boards, substrates, and IC testing burn-in systems. By 2025, the company's revenue mix by technology had already shifted clearly toward higher-end products: substrates about 58% to 59%, HDI about 27%, PCB about 11%, FPC about 2% to 3%, and others about 1%. This structure remained broadly intact in Q1 2026, at around substrates 59%, HDI 27%, PCB 11%, and FPC 2%. In other words, Unimicron is no longer an ordinary multilayer-board factory. It is closer to a manufacturer of high-end substrates and advanced interconnect platforms.
Who are the customers, and how does the company charge? Publicly verifiable materials do not directly provide a full customer list, so precise customer concentration is unknown and would require the annual report or full investor Q&A transcripts. The company has disclosed its revenue mix by application: in Q1 2026, Computer accounted for about 65%, Communication about 22%, Consumer & Others about 9%, and Automotive about 4%; for full-year 2025, the mix was roughly Computer 61%, Communication 21%, Consumer 12%, and Automotive 6%. This indicates that Unimicron mainly supplies customers related to chip packaging, servers, communications equipment, consumer electronics, and automotive electronics. Revenue is essentially driven by unit price x shipment volume of high-complexity boards and substrates. Because products require design-in, process qualification, and yield ramp-up, I believe customer switching is not easy. That is an inference based on product characteristics, not a verbatim statement from management in the materials accessed.
Is revenue recurring, stable, and predictable? Long-term demand exists, but revenue is not smooth. From 2020 to 2022, the company rode an upcycle and revenue rose from NT$87.893 billion to NT$140.489 billion; in 2023, it fell back to NT$104.036 billion; in 2024 and 2025, it recovered to NT$115.373 billion and NT$131.241 billion. This means it is not subscription-like or consumer-staples-like stable revenue. It is typical manufacturing revenue driven by cycle + product mix + utilization rate. Q1 2026 revenue further rose to NT$37.446 billion, up 24.5% year over year, but that says more about an improving cycle than about the business model becoming inherently stable.
What does the cost structure look like? Its cost structure is very similar to that of other capital-intensive electronics manufacturers: materials, labor, manufacturing overhead, and depreciation are high, and profitability is highly sensitive to capacity utilization. In 2025, cost of goods sold accounted for 86.1% of revenue and operating expenses for 8.9%; in Q1 2026, cost of goods sold fell to 82.0%, while operating expenses rose to 10.7%. This means that even when demand improves, profit leverage depends heavily on product mix and yield, not simply on price increases. Put differently, Unimicron earns money from "process + scale + cycle," not from "brand premium."
Does the company depend on a few customers, suppliers, channels, policies, or key people? The precise share of the top five customers or suppliers cannot be confirmed from the materials available in this review. But based on the application mix, the company's dependence on the computing/server chain is clearly rising, with Computer already reaching 65% of revenue in Q1 2026. The chairman changed in 2026, with Chien Shan-Chieh, who has a UMC Group background, taking over; the largest shareholder remains United Microelectronics Corporation, with a stake of about 12.97%. This suggests Unimicron is not dependent on a founder-type entrepreneur. It looks more like a specialized manufacturing platform within a group system.
Is the business simple, transparent, and easy to understand? If the stock market closed for five years, would I be willing to hold it? From the standpoint of "what it does, whom it sells to, and how it makes money," the business is understandable. From the standpoint of whether it can compound easily and with high certainty over the next decade, it is not simple, because technology transitions, yield, utilization, industry capacity, and end demand all affect returns. If the stock market closed for five years, I would be willing to own this business at a reasonable price. But at the current price, I would not. What I am willing to own is a business, not the right to own a business at any price.
Business understandability score: 4/5.
Industry and Moat
Industry stage and long-term demand The PCB/substrate industry is not a sunset industry, and long-term demand is not fake demand. Prismark's PCB reports continue to track the global PCB market, and industry organizations generally believe that after the 2023 trough and a mild recovery in 2024, 2025 entered a more visible growth phase. The company's annual report summary also noted that, driven by AI servers, low-earth-orbit satellites, and automotive electronics, the global PCB industry recovered to about US$73.6 billion in 2024. The issue is not whether long-term demand exists. The issue is whether such demand can create stable and excess returns on capital for companies. The answer is usually no, because the industry remains meaningfully cyclical.
Main competitors and industry structure The broader PCB field is fragmented. Industry commentary and annual report materials both indicate that even large players usually have only single-digit market shares. In the narrower high-end substrate segment, concentration is higher. Taiwanese companies commonly compared with Unimicron include Nan Ya PCB (8046.TW) and Kinsus (3189.TW), while in broader global PCB competition, Zhen Ding, Nippon Mektron, TTM, and others are also important players. In terms of product similarity, Nan Ya PCB and Kinsus are closer direct comparables than ordinary PCB manufacturers.
Is the industry profit pool concentrated, and what is the company's position? Unimicron's strength is not consumer branding. It lies in high-end substrates, HDI, multi-site mass production capability, and customer qualification history. The technology revenue mix in 2025 and Q1 2026 shows that the company has shifted its revenue center of gravity to the substrate business, which has higher margins and stronger technical barriers. The problem is that although substrates are better than ordinary PCBs, this is still manufacturing. Margins are pulled by the cycle, upstream materials, and expansion timing. The company's gross margin reached 35.9% in 2022, fell to 19.5% in 2023, compressed further to 14.1% in 2024, and was still only 13.9% in 2025. This shows that although the company's position is not weak, the industry profit pool is not naturally stable.
Pricing power and inflation resistance Unimicron does have pricing power, but only episodic pricing power. When ABF/high-end substrate supply is tight, manufacturers with strong yield and supply capability can obtain better prices and higher utilization. But the sharp gross-margin swing from 2022 to 2025 shows that this is not the consumer-brand type of power that says "I can raise prices forever." It is more like a cyclical advantage: stronger bargaining power in a favorable cycle and a reversion to manufacturing normality in a downturn.
Moat assessment by item Brand advantage: Weak to medium. It has no brand in the minds of end consumers, but reliable delivery and process reputation among B2B customers are valuable. Cost advantage: Medium. Scale, yield, and product mix create cost differences, but not enough to make peers unable to catch up. Scale advantage: Medium. Multiple sites, multiple product lines, and a larger capital platform form an advantage. Network effects: None. Switching costs: Medium. This is an inference based on the design-in and qualification cycles of high-end substrates/HDI, especially in server and automotive applications. Channel advantage: Weak. It is one part of the manufacturing supply chain, not the controller of the channel. Patent/license/regulatory barriers: Weak to medium. The real barriers come more from process know-how, yield, and customer qualification than from administrative licenses. Data advantage: Weak. Culture and operating capability: Medium. Financial reports and investor briefings show the company can recover revenue and profitability after a cyclical trough, but they also show that earnings quality is highly sensitive to execution and the cycle. Capital allocation capability: Below medium. It looks more like conservative financing and expansion management than excellent capital allocation focused on per-share intrinsic value.
Is the moat widening, stable, or narrowing? I would define it this way: locally strengthening, but not meaningfully widening overall. It is locally strengthening because the revenue mix is shifting further toward substrates and HDI, raising the share of advanced products. It is not meaningfully widening overall because margins had not recovered in 2025 to anywhere near the 2022 level, and free cash flow had not improved in tandem. Companies with truly wide moats usually do not see gross margin fall from 35.9% to 13.9% in just 2 to 3 years. Unimicron's advantages are real, but they are closer to "high-quality cyclical manufacturing capability" than to a "perpetual franchise."
Industry attractiveness score: 3/5. Moat strength score: 3/5.
Management and Capital Allocation
Is management honest, rational, and long-term oriented? The confirmable facts are these: in official investor briefings, the company continuously discloses revenue, gross profit, cash flow, balance sheet data, and revenue mix by technology and application. Disclosure quality is acceptable among Taiwanese manufacturing companies. In 2026, the chairmanship passed to Chien Shan-Chieh from the UMC system, reflecting governance continuity under group leadership rather than a sudden loss of control. Reuters' latest leadership information also shows that the company remains a fairly typical combination of professional management and group governance. On "candor," I have not seen obvious promotional disclosure that talks only about the story and ignores cash flow. But I also have not seen the public style of an excellent capital allocator with unusually strong self-demands around mistakes, capital efficiency, and per-share value. My judgment is: credible and steady, but not outstanding.
Ownership structure and alignment with shareholders Verifiable public information shows that United Microelectronics Corporation owns about 12.97% of Unimicron and is the most important shareholder. This structure has pros and cons. The benefit is group backing, with relatively stable governance and resource coordination. The drawback is that Unimicron is not a company where a high-ownership founder behaves like an owner and distributes cash accordingly. Alignment between investors and management/major shareholders is more like "group governance alignment" than Buffett's preferred model of "management with high ownership deeply tied to ordinary shareholders."
Is capital allocation excellent? How does the company use cash? For the past two years, I cannot call it excellent. I can only call it relatively prudent, but not friendly enough to per-share value. In cash-flow terms, the company generated NT$14.967 billion of operating cash flow in 2025, but capex was NT$25.617 billion, giving rough free cash flow of -NT$10.650 billion. To cover expansion and debt arrangements, the board approved a cash capital increase and convertible bond financing in 2025. The stated uses were repayment of maturing debt and replenishment of working capital. By Q1 2026, the cash-flow statement already showed NT$3.629 billion of cash capital increase proceeds. From the standpoint of keeping the balance sheet safe, this is rational. From the perspective of existing shareholders, it does involve dilution.
Dividends, buybacks, M&A, and debt repayment The company does pay dividends, but dividend intensity has clearly contracted. Annual cash-flow data show cash dividend payments falling from NT$12.190 billion in 2023 to NT$4.575 billion in 2024, and then to NT$2.295 billion in 2025. In the materials I accessed, I did not see buybacks worth treating as a core capital-allocation highlight. The more visible pattern is dividend contraction + cash capital increase + convertible bond issuance. On M&A, I did not find enough public evidence in the current materials to evaluate how much value acquisitions have created, so this should be marked as additional information required.
Management and capital allocation score: 3/5. The reason is simple: management does not appear irresponsible, but capital allocation looks more like serving the industry cycle and capacity expansion than being tightly centered on "maximizing per-share intrinsic value growth." For long-term owners, those two are different.
Financial Quality
Start with the most important conclusion: Unimicron's financial statements do not show obvious signs of accounting fraud, and operating cash flow has been positive over the long term, which is healthier than many concept stocks. But it is far from a "high-quality cash machine," because large amounts of cash have been consumed by capex in the past two years, leaving very limited cash truly available for shareholders. More importantly, the volatility in profitability fully exposes the cyclical nature of this industry: 2022 was a cyclical peak, and 2024 to 2025 was a recovery period, not a smooth compounding period.
Key financial metrics Scope: consolidated; unit: NT$100 million; rough FCF = operating cash flow - purchases of property, plant, equipment and investment property; EPS is basic earnings per share attributable to owners of the parent.
| Year | Revenue | Gross Margin | Operating Margin | Net Margin | Operating Cash Flow | Capex | Rough FCF | EPS |
|---|---|---|---|---|---|---|---|---|
| 2020 | 878.9 | 14.6% | 4.6% | 6.1% | 181.6 | 145.5 | 36.1 | 3.74 |
| 2021 | 1,045.6 | 22.6% | 12.6% | 12.9% | 429.4 | 231.7 | 197.7 | 8.98 |
| 2022 | 1,404.9 | 35.9% | 27.2% | 22.2% | 610.8 | 320.7 | 290.1 | 20.08 |
| 2023 | 1,040.4 | 19.5% | 8.6% | 11.8% | 309.0 | 229.4 | 79.6 | 7.88 |
| 2024 | 1,153.7 | 14.1% | 4.4% | 4.8% | 102.9 | 261.3 | -158.3 | 3.34 |
| 2025 | 1,312.4 | 13.9% | 5.1% | 5.8% | 149.7 | 256.2 | -106.5 | 4.38 |
| 2026Q1 | 374.5 | 18.0% | 7.4% | 14.4% | 58.3 | 54.8 | 3.6 | 3.28 |
The raw data in the table come from annual and quarterly financial summaries published in the company's official investor presentations. Margins and rough FCF are calculated by me using a consistent approach.
How should we read these numbers? First, revenue grew rapidly from 2020 to 2022, plunged in 2023, and recovered again in 2024 to 2025. This is a strong company in a cyclical industry, not a compounder that becomes steadier over time. Second, the margin collapse is very clear: gross margin fell from 35.9% in 2022 to 13.9% in 2025, while operating margin fell from 27.2% to 5.1%. This tells me that the high profit in 2022 looked more like a cyclical windfall than a stable structural advantage. Third, Q1 2026 statements improved significantly, but non-operating income and expenses were NT$3.542 billion, even higher than operating income of NT$2.757 billion. That means Q1's high profit cannot simply be annualized and treated as "core operating profit."
Operating cash flow, free cash flow, and profit matching If we only compare operating cash flow with net income, Unimicron is not bad: from 2020 to 2025, operating cash flow was positive every year and exceeded net income in most years. That does not fit the typical pattern of inflated profits. The real problem is capex intensity. From 2023 to 2025, capex intensity was roughly 19.5% to 22.6% of revenue, causing rough free cash flow to be negative in both 2024 and 2025. In other words, the profit is real, but much of it cannot be freely distributed to shareholders. This matters greatly to long-term value investors: a company can have real earnings and still fail to be a high-quality cash-distribution machine.
Returns on capital and asset efficiency Based on public data, Unimicron's ROE was very strong at the 2022 cyclical peak, but it had fallen significantly by 2023 to 2025. Using net income attributable to the parent and average equity as a rough calculation, ROE was about 12.7% in 2023, 5.2% in 2024, and 6.5% in 2025. Using a simplified ROIC estimate, 2023 to 2025 was roughly 10% -> 4% -> 5%. These are not bad figures, but they are clearly below the level of a business with long-term excellent capital returns. Put differently, the market is currently giving it something closer to a high-growth-stock valuation, while its historical return quality looks closer to that of an above-average manufacturing leader.
Balance sheet and survivability Unimicron's financial safety is actually decent. Reuters/LSEG showed total debt of about NT$60.28 billion in 2025 and year-end cash of about NT$54.87 billion, leaving very low net debt. In Q1 2026, the official balance sheet showed cash of NT$60.179 billion, shareholders' equity of NT$116.953 billion, and no loss of balance-sheet control. Based on 2025 EBITDA of NT$28.555 billion, net debt/EBITDA was only about 0.2x. Financial leverage itself is not the main risk. To me, Unimicron's bigger risk is not "it cannot survive," but "if bought at a high price, investors may wait a long time before returns match the price paid."
Working capital and accounting quality From the end of 2025 to Q1 2026, inventory rose from NT$17.802 billion to NT$18.936 billion, and inventory days increased from 53 days to 55 days. Net accounts receivable rose from NT$27.565 billion to NT$28.976 billion, but receivable days improved from 71 days to 69 days. This shows that the company is indeed building inventory and increasing shipments during the recovery, but there is no visible uncontrolled deterioration for now. Overall, I do not see significant evidence pointing to aggressive accounting or profit manipulation. Still, non-operating income had a relatively high weight in the most recent quarter's profit, so some caution on near-term earnings quality remains necessary.
Share count changes, dividends, and buybacks The TWSE company profile showed share capital of about NT$15.889 billion in June 2026. Public news and announcement summaries show that in January 2026, the company completed a cash capital increase, issuing 46 million shares at NT$116/share, alongside convertible bond financing approved in 2025. Roughly speaking, this created about 3% dilution for existing shareholders. For a company I would want to own over the long term, such financing is not unacceptable. But it does show that value creation here in the past two years has not come from "buybacks + per-share value increase," but from "expansion + financing + waiting for the cycle to recover."
Owner Earnings and Valuation
Core conclusion on Owner Earnings If you ask in the Buffett sense, "How much money can this company truly leave to owners in a year?" my answer is: far below the optimistic expectations implied by the current share price. In 2025, the company reported consolidated net income of NT$7.550 billion and net income attributable to the parent of NT$6.673 billion; depreciation and amortization were NT$18.773 billion; operating cash flow was NT$14.967 billion. The problem is that 2025 spending on property, plant, equipment and investment property reached NT$25.617 billion. If all capex is treated as necessary spending, then 2025 Owner Earnings on a strict cash basis were actually negative. Clearly, part of that capex was for expansion rather than maintenance, but even so, it cannot be beautified into a high-quality cash cow.
A conservative Owner Earnings estimate I use a conservative but explainable framework:
Starting point: 2025 operating cash flow of NT$14.967 billion;
Maintenance capex: because the company is in a high-end substrate and expansion cycle, I do not accept a very low estimate. Conservatively, I treat 50% to 60% of total capex as maintenance capex, or about NT$12.8 billion to NT$15.4 billion;
Working capital: since 2025 to 2026 is a recovery and expansion period, I conservatively reserve another NT$1 billion to NT$2 billion for working capital absorption.
On this basis, Unimicron's current normalized Owner Earnings are only about NT$8 billion to NT$10 billion. This already gives some leniency by treating part of expansion capex as "growth capex." Based on the current market capitalization of roughly NT$1.447 trillion, the current price corresponds to about 145x to 181x conservative Owner Earnings. Even if we crudely annualize Q1 2026 parent-company net income of NT$5.043 billion, the current market capitalization still implies an annualized P/E of about 72x. This is not value-stock valuation. It is highly optimistic growth-stock valuation.
Method 1: Owner Earnings DCF The three scenarios below already give relatively generous growth assumptions for AI/high-end substrates. The discount rate is the return I require as a conservative shareholder, not the market's "story discount rate."
| Dimension | Bear | Base | Bull |
|---|---|---|---|
| Starting Owner Earnings | NT$10 billion | NT$18 billion | NT$22 billion |
| Growth rate over next ten years | 3% | 8% | 10% |
| Discount rate | 11% | 10% | 9.5% |
| Terminal growth rate | 2.5% | 3.0% | 3.5% |
| Equity value | NT$124.9 billion | NT$383.4 billion | NT$622.8 billion |
| Per-share value | about 79 | about 241 | about 392 |
These valuations are scenario estimates based on public financial data, not management guidance. Their implied assumptions are:
Bear case: the Q1 2026 improvement is largely cyclical repair, and normalized cash-generation capacity returns to around NT$10 billion;
Base case: AI/HPC demand lifts normalized Owner Earnings to around NT$18 billion, but margins remain clearly below 2022 levels;
Bull case: the strong conditions seen in Q1 2026 last for a relatively long time, and capex efficiency improves.
Even in my relatively generous bull case, intrinsic value is only about NT$392/share. Compared with the current NT$911, the gap remains enormous.
Method 2: Relative valuation Unimicron's current valuation is roughly TWSE official PE about 134x, Reuters forward P/E about 143x, P/B about 12.8x, P/S about 10.4x, and P/CF about 46.4x. Among directly comparable Taiwanese substrate peers, Nan Ya PCB's market capitalization in early June was about NT$546.0 billion, with a Reuters-specific P/E also around 180x and P/B about 11.5x to 12.2x; Kinsus had a market capitalization of about NT$373.6 billion and a Yahoo P/E of about 211.6x. This tells me two things. First, Unimicron is not the only expensive company in the sector. Second, expensive peers do not make it cheap. More likely, the entire ABF/substrate sector is being intensely priced by the AI narrative.
Method 3: Asset or liquidation value In Q1 2026, the company had cash and cash equivalents of NT$60.179 billion, funds and investments of NT$12.645 billion, property, plant, equipment and investment property of NT$126.148 billion, total assets of NT$266.881 billion, and shareholders' equity of NT$116.953 billion. Based on share capital, book value per share was only about NT$73.6/share. Even if you believe replacement value of fixed assets or some land value is above book value, the asset approach still struggles to lift value into the several-hundred-NT-dollar range, let alone NT$911. Therefore, investing in Unimicron at the current price is almost entirely a bet on "many years of sustained high future profitability," not on an "asset discount."
Overall valuation conclusion
Conservative intrinsic value range: NT$80 to NT$120/share
Reasonable intrinsic value range: NT$140 to NT$240/share
Optimistic intrinsic value range: NT$250 to NT$390/share
Current price relative to intrinsic value: There is no discount to any of my three scenarios; it is even above the upper end of the optimistic scenario.
Required margin of safety: Given industry cyclicality and capex intensity, I would require at least a 35% to 40% discount.
Ideal buy price range: NT$90 to NT$150/share
Acceptable hold price range: NT$150 to NT$250/share
Clearly overvalued range: above NT$350/share
This set of ranges does not mean Unimicron can only be worth a few dozen NT dollars. It means that if you insist on buying from a long-term owner's perspective and require returns commensurate with risk, you cannot pay a nearly "infinitely optimistic" price for a capital-intensive and clearly cyclical manufacturer.
Margin of safety judgment The current price not only has no margin of safety, it has already entered a zone where the company must beat expectations for many consecutive years before investment returns can become barely reasonable. The most fragile assumption in the valuation is that the market assumes the uplift from AI/server demand will remain with the company for a long time, at high margins and low capital consumption. The historical financial record does not provide enough evidence to support that. For value investors, this is the classic case of a good company at a bad price.
Risks, Checklist, and Final Judgment
The most important risks and the opposing view The strongest counterargument is not complicated: bulls see the AI narrative; bears see cyclical manufacturing plus a huge valuation bubble. Bulls will say Unimicron is an indispensable ABF/HDI beneficiary of AI/HPC infrastructure. Bears will say 2022 already proved that profits in this type of company can surge and collapse, while the price the market is assigning in 2026 is no longer buying a "recovery" but buying the "perpetualization of multi-year super-cycle conditions." If, over the next 2 to 3 years, gross margin cannot return to around 20%, Owner Earnings cannot rise, and high capex plus financing remain necessary, valuation contraction will become the main source of permanent capital loss.
On specific risks, I focus most on the following categories. Competition risk: Nan Ya PCB, Kinsus, and broader global PCB/substrate manufacturers are all benefiting from the same AI narrative. No one in the industry can rest easy. Technology substitution and product migration risk: If packaging routes, customer architectures, or material systems change, current advantages may weaken. That is normal in advanced manufacturing. This risk is more an industry-characteristic inference than a specific disclosed event from the company. Cyclical risk: The margin changes from 2022 to 2025 already show that cycle swings can significantly change earnings. Customer and application concentration risk: Computer-related revenue reached 65% in Q1 2026, and dependence on the AI server/computing chain is rising. Capex risk: Operating cash flow is positive, but free cash flow was negative in 2024 and 2025, which means expansion mistakes would directly erode shareholder returns. Overvaluation risk: This is the core risk today, not a side issue. TWSE official PE has reached about 134x. Financing and dilution risk: The company has actually carried out a cash capital increase and convertible bond financing in recent years. FX, interest-rate, supply-chain, and geopolitical risks: As an export-oriented, cross-region manufacturer, these risks cannot be absent. They are just not the first balance-sheet-level risk at present.
What facts would make me admit that the current "Avoid" judgment is wrong? I would be willing to reassess if the following conditions occur:
Over the next 8 quarters, the high substrate/HDI share continues, while gross margin can stay above 20% rather than spike for one quarter and then fall back;
Normalized Owner Earnings can stabilize above NT$25 billion to NT$30 billion, and capex intensity declines significantly;
Operating cash flow and free cash flow improve together on a sustained basis, without relying on financing to raise the cash balance;
The market price falls sharply back near my reasonable value range.
Conversely, the following facts would strengthen my bearish view:
Gross margin falls back into the 13% to 15% range;
Inventory days keep rising while revenue growth slows;
Significant equity financing appears again, or high capex continues without improving cash returns;
The latest-quarter profit structure, where "non-operating income is materially higher than operating income," repeats.
Comparison with other opportunities Compared with broad-market indexes, Unimicron's advantage is upside sensitivity, while its disadvantages are single track, single company, and single valuation assumption. Compared with a diversified index such as the S&P 500, outperforming with Unimicron at the current price requires being right simultaneously on AI demand, substrate supply, company execution, the pace of capex, and the absence of a large valuation pullback. That is obviously much harder than buying an index. Compared with risk-free yield, the Reuters page showed the U.S. 10-year Treasury yield at about 4.57%. For a company whose valuation is already extremely high and whose historical free cash flow is not stable, you should demand expected returns well above that level. Based on my valuation work above, Unimicron does not currently offer such compensation. If I could hold only 5 assets, I would not put it in the portfolio.
Investment Checklist
| Question | Conclusion |
|---|---|
| Can I understand this business? | Pass |
| Does it have long-term stable demand? | Pass |
| Does it have a durable moat? | Uncertain |
| Does it have pricing power? | Fail |
| Can it generate stable free cash flow? | Fail |
| Are its returns on capital excellent? | Uncertain |
| Is management trustworthy? | Pass |
| Is capital allocation rational? | Uncertain |
| Is the balance sheet solid? | Pass |
| Is valuation below intrinsic value? | Fail |
| Is the margin of safety sufficient? | Fail |
| Would I feel comfortable holding it long term? | Fail |
| What key facts would make me sell? | Gross-margin decline, continued dilution, free-cash-flow deterioration, worsening application mix |
| Am I only tempted to buy because the share price has risen or market sentiment is strong? | Very likely; requires serious self-check |
The conclusions in the table come from the integrated assessment above of business model, earnings volatility, capex, financing actions, and current valuation.
Final investment conclusion
【Final Rating】 Avoid
【One-sentence investment thesis】 Unimicron is a reasonably competitive high-end substrate/HDI manufacturer, but the current price has prepaid too much multi-year AI strength and high profitability. For conservative long-term value investors, the odds are clearly unattractive.
【Core bullish arguments】
The business is understandable, and the revenue mix has clearly concentrated toward higher-end products such as substrates and HDI.
Fundamentals improved visibly in Q1 2026, with revenue up about 24.5% year over year and gross margin recovering to 18.0%.
The balance sheet is not fragile. Net leverage is low, and short-term debt repayment is not the main concern.
The long-term demand direction from AI/servers/high-performance computing is real.
【Core bearish arguments】
The industry and the company's earnings are highly cyclical. The margin swings from 2022 to 2025 already prove this is not a stable compounder.
Free cash flow was negative in 2024 and 2025, showing that real distributable cash flow is unattractive.
Non-operating contribution was high in the latest quarter, so earnings quality cannot be simply annualized.
The current valuation is extremely expensive. TWSE/Reuters PE is about 134x to 143x, far beyond my acceptable range.
There has been a cash capital increase and convertible bond financing in recent years, diluting shareholders.
【Key assumptions】
AI/HPC demand can structurally lift substrate profitability rather than merely create a short-term boom.
Capex will not remain for a long time at a level that suppresses free cash flow.
The competitive landscape will not quickly deteriorate because of new capacity expansions.
Within the current earnings improvement, the contribution from core operations will increase rather than continuing to rely on non-operating items.
【Fair Buy Price】 NT$90 to NT$150/share. Basis: I apply a 35% to 40% margin-of-safety discount to my NT$140 to NT$240/share reasonable value range. Given the industry's strong cyclicality and high capital consumption, I am unwilling to pay a high premium for a "manufacturing leader with a medium moat."
【Target Holding Period】 If the price enters a reasonable range, I think this type of asset is suitable for a 5 to 10 year holding period; at the current price, I do not recommend establishing a long-term value position.
【Expected Annualized Return】 Based on the three scenarios above and assuming that long-term market price reverts toward fundamentals:
Bear case: about -20% to -22%/year
Base case: about -12% to -17%/year
Bull case: about -8%/year
These returns assume purchase at the current price of about NT$911 and reversion to my estimated intrinsic value range after ten years. They sound harsh, but that is exactly why the main problem today is not that the company is bad. The price is too high.
【Maximum Loss Risk】 If the market eventually reprices Unimicron as an "excellent but cyclical manufacturer" rather than a "perpetual high-growth pure AI beneficiary," a share-price reversion toward NT$150 to NT$250 or even lower is not unimaginable. Relative to the current price, that would imply a 70% to 85% level of capital loss. If an industry downturn coincides with a valuation derating, the decline could be larger. This risk is not bankruptcy. It is valuation mean reversion after buying at a high price.
【Tracking Indicators】
Whether substrate revenue share remains above 58% to 60%
Whether Computer/AI/HPC application share continues to rise and is not a short-term spike
Whether gross margin can stabilize above 18% to 20%
Whether operating margin improves at the same time, rather than relying only on non-operating items
Whether operating cash flow and free cash flow strengthen together
Whether annual capex clearly falls from the NT$25 billion level
Whether equity financing or convertible bond expansion appears again
Whether inventory days and receivable days deteriorate
Whether monthly revenue stays high without obvious inventory-clearance pressure
Whether net debt/EBITDA remains low.
【Signals That Would Trigger Reassessment】
Gross margin remains above 20% for 4 to 8 consecutive quarters, with operating margin rising at the same time
Free cash flow turns positive and stays positive continuously
Capex falls, while revenue and profit still grow
Management stops dilutive financing and shifts toward greater emphasis on per-share value
Valuation falls materially back into my reasonable range
Conversely, if non-operating contribution continues to be much higher than operating profit, inventory builds rapidly, or another large financing occurs, I would strengthen the Avoid judgment.
【Final Recommendation】 Put calmly, Unimicron is not a company that "cannot be bought"; it is a stock that "should not be bought at the current price." If you are willing to act as a long-term business owner, your attention should be on whether the company can continuously produce high-quality Owner Earnings, whether it has a truly widening moat, and whether the purchase price leaves enough room for mistakes. At today's price, I do not see that room. The most prudent approach is not to chase strength, but to wait for valuation to return to a range where fundamentals can work for you.
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free